Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/128812SPORE COMPOSITIONS, PRODUCTION AND USES THEREOF
WO 23.06.2022
Int.Class C12N 1/20
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
20Bacteria; Culture media therefor
Appl.No PCT/EP2021/085278 Applicant BASF SE Inventor MAY, Tobias
The present invention is concerned with providing spore compositions and methods of producing such compositions. The invention also is concerned with plant protection products and benefiting from such spore compositions and uses of such compositions for the benefit of plants, reduction of pathogen emissions to nearby areas and for the benefit of animals or humans. Furthermore, the invention is concerned with methods of efficient fermentation.
2.WO/2022/129097SIRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES
WO 23.06.2022
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
Appl.No PCT/EP2021/085766 Applicant SYLENTIS SAU Inventor JIMÉNEZ, Ana Isabel
The invention relates to siRNA molecules and compositions which modulate the expression of the Eukaryotic Translation Elongation Factor 1 Alpha 2 (EEF1A2) gene, which can be useful in reducing viral replication and managing viral infections or infestations. Such molecules and compositions can be useful in treating or preventing infection with RNA viruses in humans (for example, coronaviruses such as SARS-CoV-2 or influenza viruses such as influenza virus type A) or in agriculturally important plants.
3.WO/2022/129472SAFE IMMUNO-STEALTH CELLS
WO 23.06.2022
Int.Class C12N 5/0735
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
073Embryonic cells or tissues; Foetal cells or tissues
0735Embryonic stem cells; Embryonic germ cells
Appl.No PCT/EP2021/086399 Applicant NOVO NORDISK A/S Inventor CHAPLIN, Jay
The present invention relates to safe and immuno-stealth implantable cells and their use to prevent, treat or cure a disease.
4.WO/2022/129517MEANS AND METHODS FOR DETOXIFYING OCHRATOXIN A
WO 23.06.2022
Int.Class C12N 9/80
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
14Hydrolases (3.)
78acting on carbon to nitrogen bonds other than peptide bonds (3.5)
80acting on amide bonds in linear amides
Appl.No PCT/EP2021/086480 Applicant ERBER AKTIENGESELLSCHAFT Inventor PRASAD, Shreenath
The present invention relates to novel polypeptides capable of detoxifying Ochratoxin A (OTA) and methods (e.g., for detoxifying mycotoxins) based thereon. The present invention further relates to compositions, kits, transgenic plants, transgenic seeds, transgenic pollen grains, foodstuff, intermediate foodstuff; fodder, intermediate fodder; feed, intermediate feed; additive (e.g., foodstuff-, fodder- or feed additive), intermediate additive (e.g., foodstuff-, fodder- or feed intermediate additive); detoxifying agent, intermediate detoxifying agent; nutritional supplement, intermediate nutritional supplement, prebiotic, intermediate prebiotic and/or mixture/s thereof comprising one or more of the polypeptides capable of detoxifying Ochratoxin A (OTA).
5.WO/2022/130162A SUPPLEMENT COMPOSITION FOR CELL CULTURE
WO 23.06.2022
Int.Class C12N 5/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
Appl.No PCT/IB2021/061622 Applicant CLEAR MEAT PRIVATE LIMITED Inventor K DHAR, Pawan
The present invention provides a supplement composition and method of preparation thereof for cell culture. The supplement composition comprises natural substances without using any animal based serum. The present invention provides slaughter free, effective and affordable supplement for growth of animal cells that eliminates or minimizes dependency on the fetal bovine serum.
6.WO/2022/131182EPIDERMAL STEM CELL PROLIFERATION-PROMOTING AGENT
WO 23.06.2022
Int.Class A61K 8/49
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
49containing heterocyclic compounds
Appl.No PCT/JP2021/045725 Applicant SHISEIDO COMPANY, LTD. Inventor TOBITA Ryozo
The present disclosure pertains to provision of a composition that is effective in improving conditions of skin in terms of maintenance and improvement of quality of life (QOL) related to both health and beauty. More specifically, the present disclosure pertains to a composition containing 1-(2-hydroxyethyl)-2-imidazolidinone or a derivative thereof, and a pyridine carboxamide. This promotes the proliferation of epidermal stem cells and the proliferation of keratinocytes, and therefore, can be suitably used as a cosmetic composition such as a cosmetic that is effective in improving conditions of skin.
7.WO/2022/127372CAR-INKT WITH HIGH AMPLIFICATION, SURVIVAL CAPACITY AND TUMOR KILLING EFFECT AND USE THEREOF
WO 23.06.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2021/125615 Applicant BEIJING GENE KEY LIFE TECHNOLOGY CO., LTD. Inventor LYU, Jun
Provided in the present application is a chimeric antigen receptor, including a GPC3 antigen binding domain, an ICD1, ICD2 or ICD3 intracellular signal stimulation domain with amino acid sequences of SEQ ID NOs: 29, 31 and 33, respectively, and an IL-15-IL-15α fusion protein with an amino acid sequence of SEQ ID NO:7. After the chimeric antigen receptor is transferred into immune cells, especially iNKT cells, the cell proliferation rate, survival time and tumor killing effect can be effectively improved. Further provided in the present application are a corresponding expression vector, a transduction system, a pharmaceutical use, independent ICD1, ICD2 and ICD3 intracellular signal stimulation domains, and an IL-15-IL-15α fusion protein.
8.WO/2022/127882METHOD AND KIT FOR SCREENING CANDIDATE DRUGS TARGETING CD47-SIRPα IMMUNE CHECKPOINT
WO 23.06.2022
Int.Class G01N 21/64
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
21Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
63optically excited
64Fluorescence; Phosphorescence
Appl.No PCT/CN2021/138975 Applicant NANJING PROBIO BIOTECH CO., LTD. Inventor JIA, Wenshuang
Disclosed are a method and a kit for screening candidate drugs targeting the CD47-SIRPα immune checkpoint. The method comprises contacting a target cell analog, a candidate drug targeting the CD47-SIRPα immune checkpoint with an effector cell, wherein the target cell analog provides a CD47 protein and a T cell receptor (TCR) agonist, the effector cell includes a reporter gene and a stably expressed SIRPα and TCR; incubating the mixture of the target cell analog, the candidate drug and the effector cell; and detecting the expression of the reporter gene or the expression level thereof to determine the blocking of the candidate drug on the CD47-SIRPα immune checkpoint. The method and kit can qualitatively or quantitatively evaluate the pharmacodynamic index of the drug in an high-throughput manner in vitro, and an evaluation result has a high repeatability and a high sensitivity.
9.WO/2022/130732HYGIENE PRODUCT DERIVED FROM SEAWEEDS AND EXTRACT THEREOF, FOR ORAL CAVITY, NOSTRILS, AND THROAT
WO 23.06.2022
Int.Class A01N 65/03
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
65Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
03Algae
Appl.No PCT/JP2021/036078 Applicant NAKAMURA Shoichi Inventor NAKAMURA Shoichi
Provided is a hygiene product derived from seaweeds and an extract thereof, for oral cavity, nostrils, or throat. This hygiene product for the oral cavity or nostrils includes a mouth washing liquid and a cleaning agent for the oral cavity, nasal cavity, or throat. The hygiene product is derived from seaweeds such as kelp, wakame, and green laver and/or an extract thereof, and has a deactivating action against viruses including SARS-CoV-2, influenza virus, and norovirus, and also has antibacterial action against bacteria including Escherichia coli and Staphylococcus aureus. Here, the hygiene product for oral cavity includes candies, chewing gums, and general chewing foods that are held in one’s mouth for at least a certain period of time and facilitates saliva secretion.
10.WO/2022/132817SILICIFIED TUMOR CELL COMPOSITIONS AND METHODS
WO 23.06.2022
Int.Class A61K 35/13
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
13Tumour cells, irrespective of tissue of origin
Appl.No PCT/US2021/063386 Applicant UNM RAINFOREST INNOVATIONS Inventor SERDA, Rita E.
In one aspect, a method generally includes obtaining a dried silicified cell that has been stored for at least 24 hours without cryopreservation and rehydrating the dried silicified cell in a pharmaceutically acceptable carrier. The method can further include surface modifying the silicified cell with at least one immunogenic molecule. The method can further include administering the rehydrated silicified cell to a subject. In some embodiment, the dried silicified cell has been stored for at least 14 days without cryopreservation. In another aspect, a method of treating a tumor in a subject generally includes administering to the subject a chemotherapeutic agent effective to treat the tumor and administering to the subject a silicified cell vaccine effective to treat the tumor.